



IMDRF
International Medical Device
Regulators Forum

EU2023
EUROPEAN UNION
Chair

09:10 – 09:25

Canada



David Boudreau

Director General, Medical Devices Directorate,
Health Canada



Regulatory and Policy Updates Health Canada

David Boudreau

Director General, Medical Devices Directorate

March 28, 2023

Overview

- Continuing to Enable Access to COVID-19 Devices
- Expanding Device Terms and Conditions
- New Guidance on Clinical Evidence Requirements
- Launch of Interactive Submission Tool: eSTAR
- Upcoming Public Consultations

Continuing to Enable Access to COVID-19 Devices

- Health Canada used temporary measures (Interim Orders No. 1, 2, 3) to expedite the review of, and access to, COVID-19 medical devices in Canada.
- On February 22, 2023, Health Canada introduced [Regulations Amending the Medical Devices Regulations \(Interim Order No. 3\)](#) to:
 - Enable COVID-19 medical devices to continue to be imported and sold after the expiry of Interim Order No. 3 on February 21, 2023.
 - Maintain most authorization flexibilities for authorizations where an urgent public health continues to exist.
 - Provide an expedited authorization pathway for new COVID-19 medical devices that are on the **List of Medical Devices for an Urgent Public Health Need in Relation to COVID-19** (UPHN list).




Continuing to Enable Access to COVID-19 Devices

- Edits to the UPHN list can be made by the Minister of Health and do not require regulatory amendments. This provides agility to address public health needs as they emerge.

Category of medical devices
testing devices that offer a multiplex feature for detecting COVID-19 and other respiratory pathogens (for example, influenza A, B and respiratory syncytial virus)
molecular or antigen tests that offer saliva sample types
testing devices that offer other unique sample types
testing devices that offer a unique feature that meets a clinical or accessibility need
testing devices that offer environmentally sustainable features
medical devices that do not belong to any other category of medical devices set out in Part 2 of the List for which an application for an authorization was submitted to the Minister under Interim Order No. 3 ¹ before the day on which Part 1.1 of the MDR came into force, and in respect of that application: <ul style="list-style-type: none">• no decision had been made under the Interim Order before that day,• no decision has been made under Part 1.1 of the Regulations, and• the applicant has not withdrawn the application.

Expanding Device Terms and Conditions



- As part of the **Agile Licensing** initiative, Health Canada is proposing expanded Terms and Conditions (T&Cs) regulations to support the life cycle approach for regulating medical devices.
- These proposed regulations provide us with authorities to:
 - expand the scope of use of T&Cs and;
 - impose or amend T&Cs at any time during the medical device's life
- The [consultation](#) on the proposed regulations and corresponding [guidance document](#) is open until the end of April.
- Health Canada also plans to publish information about the T&Cs that have been imposed on medical device licences, to increase transparency and communicate risks.

New Guidance on Clinical Evidence Requirements

- Guidance on Clinical Evidence Requirements for medical devices was published in November 2022.



The composite image includes four distinct elements: a blue circular icon with a DNA helix and three human figures; a line graph with an upward trend; the SGBA logo (St. Germain's Biomedical Agency) featuring the letters 'SGBA' and a colorful cross; and an icon of a magnifying glass over a document.



The screenshot shows the Government of Canada website page for 'Guidance on clinical evidence requirements for medical devices: Overview'. The page includes a navigation menu, a breadcrumb trail, and a table of contents with sections like 'Overview', 'Submitting clinical evidence', and 'Comparator devices'. The date published is November 15, 2022. The 'On this page' section lists links for 'Purpose', 'Scope and application', 'Definitions', and 'Note about guidance documents in general'.

- Guidance includes information on:
 - when clinical data/evidence is required
 - the common methods to generate clinical data
 - how to compare devices appropriately
 - sex, gender, and population considerations

Launch of Interactive Submission Tool: eSTAR


eSTAR is an interactive PDF form that guides applicants through the process of preparing a comprehensive medical device submission.

- Features in this template include the integration of multiple resources, automatic verification and guided construction for each submission section.

On January 10th, 2023, Health Canada launched two eSTAR pilots:

- Joint Health Canada and U.S. Food and Drug Administration [pilot](#):
 - Enables manufacturers to submit an application to both jurisdictions using a common submission building tool (eSTAR). While the content will be dictated by each jurisdiction's requirements, a common format will be used (IMDRF's Table of Contents structure).
 - The joint pilot is now full, having reached its total of 9 participants.
- Health Canada-only [pilot program](#):
 - Provides opportunity for manufacturers to apply to Health Canada using the eSTAR tool.
 - Pilot is still accepting participants.

Upcoming Health Canada Public Consultations



Thank you/Questions

Email david.boudreau@hc-sc.gc.ca

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.